Epigral Limited, one of India’s leading integrated chemical manufacturers, has announced its financial results for the quarter ended June 30, 2025 (Q1FY26). The company reported a revenue of ₹615 crore, reflecting a 6% year-on-year decline compared to ₹654 crore in the same quarter last year (Q1FY25).
Despite the dip in top-line performance, EBITDA stood at ₹163 crore, down 7% YoY. However, EBITDA margins remained steady at 27%, supported by continued operational efficiency and a strategic focus on product mix.
Net profit (PAT) came in at ₹160 crore, which includes a deferred tax liability benefit of ₹81 crore. Excluding this, the adjusted PAT stood at ₹79 crore, slightly lower than ₹86 crore in Q1FY25.
Operationally, plant utilization stood at 73% during the quarter. Return on Capital Employed (ROCE) improved to 24% from 21% a year earlier, driven by better profitability. Additionally, the company’s Net Debt/EBITDA ratio dropped significantly to 0.6x, compared to 1.6x in the previous year, reflecting a stronger balance sheet position.
Revenue from the company’s Derivatives & Specialty Chemicals segment contributed 50% to the overall revenue.
